-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec content team editor On November 17, Astellas Pharma announced that zolbetuximab, an investigational antibody therapy targeting Claudin18.
2 (CLDN18.
2), in combination with chemotherapy, met the primary endpoint in a Phase 3 clinical trial for the first-line treatment of locally advanced unresectable or metastatic gastric cancer, significantly prolonging progression-free survival (PFS)
in patients.
Moreover, the study also met the secondary endpoint of overall survival (OS), significantly extending the patient's life
compared with chemotherapy.
CLDN18.
2 is a popular target for gastrointestinal cancer that has received widespread attention in recent years, and zolbetuximab is the first CLDN18.
2-targeted therapy
to enter the phase 3 clinical development stage.
The results of this positive Phase 3 clinical trial further validate the potential
of CLDN18.
2-targeted therapy for the treatment of gastrointestinal cancers.
Patients with stomach cancer are usually diagnosed at an advanced stage or metastasis
.
Patients with metastatic gastric cancer have a 5-year survival rate of only about 6%, and they are in urgent need of innovative therapies
.
Claudin (CLDN) is an important protein in the tight junction of normal tissues, with 4 transmembrane domains, which are involved in the regulation
of processes such as paracellular permeability and conductance.
CLDN
was first discovered in 1998 by Japanese scientist Dr.
Shoichiro Tsukita and colleagues.
The CLDN family contains at least 27 members, of which CLDN18 has two isomers
, CLDN18.
1 and CLDN18.
2.
▲ Dear readers and friends, before you know it, 2022 has come to an end
.
Looking forward to the new year, in order to have a more comprehensive understanding of the views and insights of friends in the biomedical industry on the development of the industry, we invite you to spend 1 minute in your busy schedule to fill out this questionnaire (long press to scan the code, or
2 (CLDN18.
2), in combination with chemotherapy, met the primary endpoint in a Phase 3 clinical trial for the first-line treatment of locally advanced unresectable or metastatic gastric cancer, significantly prolonging progression-free survival (PFS)
in patients.
Moreover, the study also met the secondary endpoint of overall survival (OS), significantly extending the patient's life
compared with chemotherapy.
CLDN18.
2 is a popular target for gastrointestinal cancer that has received widespread attention in recent years, and zolbetuximab is the first CLDN18.
2-targeted therapy
to enter the phase 3 clinical development stage.
The results of this positive Phase 3 clinical trial further validate the potential
of CLDN18.
2-targeted therapy for the treatment of gastrointestinal cancers.
Patients with stomach cancer are usually diagnosed at an advanced stage or metastasis
.
Patients with metastatic gastric cancer have a 5-year survival rate of only about 6%, and they are in urgent need of innovative therapies
.
Claudin (CLDN) is an important protein in the tight junction of normal tissues, with 4 transmembrane domains, which are involved in the regulation
of processes such as paracellular permeability and conductance.
CLDN
was first discovered in 1998 by Japanese scientist Dr.
Shoichiro Tsukita and colleagues.
The CLDN family contains at least 27 members, of which CLDN18 has two isomers
, CLDN18.
1 and CLDN18.
2.
▲ Dear readers and friends, before you know it, 2022 has come to an end
.
Looking forward to the new year, in order to have a more comprehensive understanding of the views and insights of friends in the biomedical industry on the development of the industry, we invite you to spend 1 minute in your busy schedule to fill out this questionnaire (long press to scan the code, or
